eCite Digital Repository
Identification of a novel recurrent EEF2 gene amplification in familial prostate tumors
Citation
Raspin, K and Marthick, JR and Donovan, S and Blizzard, L and Malley, RC and Jung, C-H and Banks, A and Redwig, F and Skala, M and Dickinson, JL and FitzGerald, LM, Identification of a novel recurrent EEF2 gene amplification in familial prostate tumors, Genes, Chromosomes and Cancer pp. 1-9. ISSN 1045-2257 (2022) [Refereed Article]
 | PDF Pending copyright assessment - Request a copy 1Mb |
Abstract
Recurrent tumor copy number variations (CNVs) in prostate cancer (PrCa) have predominantly been discovered in sporadic tumor cohorts. Here, we examined familial prostate tumors for novel CNVs as prior studies suggest these harbor distinct CNVs. Array comparative genomic hybridization of 12 tumors from an Australian PrCa family, PcTas9, highlighted multiple recurrent CNVs, including amplification of EEF2 (19p13.3) in 100% of tumors. The EEF2 CNV was examined in a further 26 familial and seven sporadic tumors from the Australian cohort and in 494 tumors unselected for family history from The Cancer Genome Atlas (TCGA). EEF2 overexpression was observed in seven PcTas9 tumors, in addition to seven other predominantly familial tumors (ntotal = 34%). EEF2 amplification was only observed in 1.4% of TCGA tumors, however 7.5% harbored an EEF2 deletion. Analysis of genes co-expressed with EEF2 revealed significant upregulation of two genes, ZNF74 and ADSL, and downregulation of PLSCR1 in both EEF2 amplified familial tumors and EEF2 deleted TCGA tumors. Furthermore, in TCGA tumors, EEF2 amplification and deletion were significantly associated with a higher Gleason score. In summary, we identified a novel PrCa CNV that was predominantly amplified in familial tumors and deleted in unselected tumors. Our results provide further evidence that familial tumors harbor distinct CNVs, potentially due to an inherited predisposition, but also suggest that regardless of how EEF2 is dysregulated, a similar set of genes involved in key cancer pathways are impacted. Given the current lack of gene-based biomarkers and clinical targets in PrCa, further investigation of EEF2 is warranted.
Item Details
| Item Type: | Refereed Article |
|---|---|
| Keywords: | prostate cancer, somatic mutations, gene fusions |
| Research Division: | Biomedical and Clinical Sciences |
| Research Group: | Oncology and carcinogenesis |
| Research Field: | Predictive and prognostic markers |
| Objective Division: | Health |
| Objective Group: | Clinical health |
| Objective Field: | Treatment of human diseases and conditions |
| UTAS Author: | Raspin, K (Dr Kelsie Raspin) |
| UTAS Author: | Marthick, JR (Mr James Marthick) |
| UTAS Author: | Blizzard, L (Professor Leigh Blizzard) |
| UTAS Author: | Malley, RC (Dr Roslyn Malley) |
| UTAS Author: | Banks, A (Mrs Annette Banks) |
| UTAS Author: | Dickinson, JL (Professor Joanne Dickinson) |
| UTAS Author: | FitzGerald, LM (Dr Liesel FitzGerald) |
| ID Code: | 154772 |
| Year Published: | 2022 |
| Deposited By: | Menzies Institute for Medical Research |
| Deposited On: | 2023-01-05 |
| Last Modified: | 2023-01-18 |
| Downloads: | 0 |
Repository Staff Only: item control page